With Phase I data confirming the existing safety profile from the BelCHOP (Beleodaq with CHOP) study in the treatment of frontline PTCL, the path is now clear for initiation of the planned Phase III trial during H116 with partner Spectrum. Beleodaq is one of a trio of orphan oncology assets under development at Onxeo (PA:C4X), also including Livatag (liver cancer), which has now completed seven safety reviews, and Validive (oral mucositis arising from chemoradiotherapy). New preclinical collaborations for Livatag and Beleodaq could further expand the potential of both.
To read the entire report Please click on the pdf File Below